DCLL9718S / Roche - LARVOL DELTA

A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. (PubMed, Am J Hematol) - No abstract available

Clinical • Journal • P1 data • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy (clinicaltrials.gov) - P1; N=19; Completed; Sponsor: Genentech, Inc.; Terminated ➔ Completed

Trial completion

"$RHHBY discontinuations: RG6109 undiscl ADC; RG6123 anti-CEA MAb; RG6146 bromodomain inh; RG6148 undisclosed (Her2+ breast cancer); RG7625 cathepsin S inh" (@JacobPlieth)

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy (clinicaltrials.gov) - P1; N=19; Terminated; Sponsor: Genentech, Inc.; N=164 ➔ 19; Trial completion date: Nov 2022 ➔ Jul 2019; Recruiting ➔ Terminated; Trial primary completion date: Nov 2022 ➔ Jul 2019; Due to an unfavorable benefit-risk profile the Sponsor has decided to not pursue further development of DCLL9718S and the ongoing clinical trial was closed.

Clinical • Combination therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial termination

"Anyone know the mechanisms of RG6109 and/or RG6148? $RHHBY" (@JacobPlieth)

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy (clinicaltrials.gov) - P1; N=164; Recruiting; Sponsor: Genentech, Inc.; N=110 ➔ 164

Clinical • Combination therapy • Enrollment change

A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy (clinicaltrials.gov) - P1; N=110; Recruiting; Sponsor: Genentech, Inc.; Trial completion date: Sep 2023 ➔ Nov 2022; Trial primary completion date: Sep 2023 ➔ Nov 2022

Clinical • Combination therapy • Trial completion date • Trial primary completion date